Avastin Added To Tarceva/Gemcitabine Fails To Prolong Survival In Phase III Pancreatic Cancer Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche-sponsored trial did not meet the primary endpoint of overall survival, but did show some clinical benefits.
You may also be interested in...
Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.
Avastin Fails First-Line Pancreatic Cancer Trial, But Pancreatic Program Will Continue
Genentech and partner Roche await results from another first-line pancreatic cancer trial, AVITA, with enrollment slated to complete by year-end.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.